Splash Beverage Group Expands CannEpil License into Veterinary Therapeutics

Corporate Action
โดย GlobeNewswire·Read original
Summary · why it matters

Splash Beverage Group has expanded its exclusive global license for CannEpil to include veterinary therapeutic applications, creating a second FDA-regulated pharmaceutical development program alongside its existing human pharmaceutical program. The expanded field of use grants Splash exclusive worldwide rights to develop, manufacture, commercialize, market and distribute CannEpil for veterinary diseases and conditions. CannEpil is a proprietary pharmaceutical-grade cannabinoid formulation consisting of CBD and THC isolates manufactured under EU-GMP standards, originally developed for drug-resistant epilepsy and assigned an IND application number by the FDA for its human program. Splash intends to initially evaluate CannEpil for companion-animal oncology and chronic pain management, with canine indications as the initial focus, and will pursue U.S. regulatory approval through the FDA Center for Veterinary Medicine's INAD and Conditional Approval pathways. The global veterinary pain management market was valued at approximately $2.6 billion in 2024 and is projected to reach approximately $3.8 billion by 2030, while the veterinary oncology market is estimated between approximately $900 million and $1.7 billion. Under the license amendment, Splash will pay Argent BioPharma Limited a 10% royalty on net revenues from veterinary applications, and the company is finalizing a strategic joint venture with an established cannabinoid pharmaceutical company to lead the veterinary development program.

Impact on stocks 1

Consumer Staples▲ · 1 stocks
Splash Beverage Group Inc
SBEV
▲ PositiveTechnologyrelevance

Expanded CannEpil license into veterinary therapeutics creates a second FDA-regulated program, opening new revenue streams in growing markets.

Off-coverage companies 1

Argent BioPharma LimitedPrivate▲ Positive
Demandrelevance

As licensor, Argent BioPharma will receive a 10% royalty on net revenues from veterinary applications, benefiting from Splash's development efforts.

© 2026 MarketDXNews